The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vanichseni S, Wongsuwan B, Choopanya K, Wongpanich K. 1991. A controlled trial of methadone maintenance in a population of intravenous drug users in Bangkok: Implications for prevention of HIV. The International Journal of Addictions. 26(12):1313– 1320.
Washton AM, Pottash AC, Gold MS. 1984. Naltrexone in addicted business executives and physicians. Journal of Clinical Psychiatry. 45(9 pt 2):39–41.
WHO (World Health Organization). 2004a. Evidence for Action: Effectiveness of Community-Based Outreach in Preventing HIV/AIDS Among Injecting Drug Users. Geneva, Switzerland: WHO.
WHO. 2004b. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Guidelines on Care, Treatment and Support for Women Living withHiv/Aids and Their Children in Resource-Constrained Settings. Geneva, Switzerland: WHO.
WHO. 2005a. Evidence for Action: Effectiveness of Drug Dependence Treatment in Preventing HIV Among Injecting Drug Users. Geneva, Switzerland: WHO.
WHO. 2005b. Policy and Programming Guide for HIV/AIDS Prevention and Care AmongInjecting Drug Users. Geneva, Switzerland: WHO.
WHO, UNODC, UNAIDS. 2004. Substitution Maintenance Therapy in the Management ofOpioid Dependence and HIV/AIDS Prevention: Position Paper. Geneva, Switzerland: WHO.
Wiebel WW, Jimenez A, Johnson W, Ouellet L, Jovanovic B, Lampinen T, Murray J, O’Brien MU. 1996. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: A four-year prospective study. Journal of Acquired Immune Deficiency Syndromesand Human Retrovirology. 12(3):282–289.
Williams AB, McNelly EA, Williams AE, D’Aquila RT. 1992. Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care. 4(1): 35–41.